ly3437943 retatrutide A Study of (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Retatrutide (LY3437943) | GCGR/GLP-1R/GIPR Agonist

Male C57Bl/6 mice (Charles River, UK) were fed a 60% high fat diet (D12492, Research Diets, USA) for 3 months prior to the study to induce obesity and glucose intolerance

ProulxJJoshiCVijayaraghavaluSSaraswathyMLabhasetwarVGhorpadeAet alArginine-modified polymers facilitate poly (lactide-co-glycolide)-based nanoparticle gene delivery to primary human astrocytes

Half-map FSC curves were calculated before (red) and after (blue) PostProcesss, overlaid with a model-map FSC which is calculated between the final map and structural model

The typical starting dose is 10 mg once daily, which may be adjusted based on clinical response and tolerability

**Tartrazine: may have an adverse effect on activity and attention in children